MedTrace Logo

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT05666960 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-29

No results posted yet for this study

Summary

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis.

Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.

Conditions

  • Ulcerative Colitis Chronic Mild
  • Ulcerative Colitis Chronic Moderate
  • Ulcerative Colitis Chronic
  • Ulcerative Colitis

Interventions

DRUG

R-3750

Probiotic

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • Rise Therapeutics LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2026-07-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05666960 on ClinicalTrials.gov